Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maze Therapeutics (MAZE) Cash & Equivalents (2024 - 2025)

Maze Therapeutics has reported Cash & Equivalents over the past 2 years, most recently at $189.2 million for Q4 2025.

  • Quarterly Cash & Equivalents fell 3.84% to $189.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $189.2 million through Dec 2025, down 3.84% year-over-year, with the annual reading at $189.2 million for FY2025, 3.84% down from the prior year.
  • Cash & Equivalents was $189.2 million for Q4 2025 at Maze Therapeutics, down from $316.8 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $316.8 million in Q3 2025 and troughed at $30.0 million in Q1 2024.